CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 98 enrolled / 98 target
Drug / intervention
Additional Vulvar Re-Antisepsis Before Cystoscopyprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07232446
NCT07232446N/ACompletedHigh Momentum (13.6/mo)Completion was 3mo ago

Effect of Vulvar Re-Antisepsis Before CO₂ Cystoscopy Performed After Laparoscopic Hysterectomy on Postoperative Urinary Infections

Alaattin Karabulut·observational·Posted Nov 18, 2025·Updated Jun 22, 2026

In Brief

An observational study evaluating Additional Vulvar Re-Antisepsis Before Cystoscopy for Postoperative Urinary Tract Infection and 3 related conditions. Completed, enrolled 98 participants across 1 site.

Signals

Enrolling ahead of pace

Detailed Summary

This prospective observational study aims to evaluate whether additional vulvar re-antisepsis before intraoperative cystoscopy reduces the incidence of postoperative urinary tract infections (UTIs) in patients undergoing total laparoscopic hysterectomy for benign indications. In our institution, cystoscopy is routinely performed at the end of laparoscopic hysterectomy using carbon dioxide (CO₂) as the distension medium to assess bladder integrity and ureteral jet flow. However, potential contamination from the vaginal flora during cystoscopy may increase the risk of postoperative UTI. The study will compare two groups of patients: those receiving standard preoperative antisepsis only and those undergoing additional vulvar re-antisepsis immediately before cystoscopy. The primary outcome is the incidence of postoperative UTI diagnosed according to CDC criteria. Secondary outcomes include cystoscopy duration, catheterization time, and need for postoperative antibiotic therapy. Findings from this study may help determine whether an additional antisepsis step can improve infection control during laparoscopic hysterectomy.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesTurkey (Türkiye)
Collaborators--

Timeline

N/ACompletedFinished
2026
First PostedNov 18, 2025
Enrollment StartNov 25, 2025
Primary CompletionMar 10, 2026
Study CompletionApr 15, 2026
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 7 months ago

Arms & Interventions

Standard Antisepsisother

Patients undergoing total laparoscopic hysterectomy who receive routine preoperative vulvar antisepsis only. Cystoscopy is performed at the end of the procedure using carbon dioxide (CO₂) as the distension medium, without any additional re-antisepsis before cystoscope insertion.

Re-Antisepsis Before Cystoscopyother

Patients undergoing total laparoscopic hysterectomy who receive additional vulvar re-antisepsis immediately before intraoperative cystoscopy. The cystoscopy is performed using carbon dioxide (CO₂) as the distension medium to evaluate bladder integrity and ureteral jets.

Procedure: Additional Vulvar Re-Antisepsis Before Cystoscopy

Interventions

Additional Vulvar Re-Antisepsis Before Cystoscopyprocedure

In this observational cohort, some patients receive an additional vulvar re-antisepsis immediately before intraoperative cystoscopy during total laparoscopic hysterectomy. The antisepsis is performed using standard povidone-iodine solution prior to cystoscope insertion. Cystoscopy is conducted using carbon dioxide (CO₂) as the distension medium.